Vivesto AB Reports Progress in Cancer Treatment Programs

Vivesto AB ADR ( (OASMY) ) has released its Q3 earnings. Here is a breakdown of the information Vivesto AB ADR presented to its investors.

Vivesto AB is a development company focused on creating new treatment options for difficult-to-treat cancers in humans and animals, with a portfolio that includes veterinary oncology program Paccal Vet, cancer program Cantrixil, and the cancer product Apealea. In its latest earnings report for January to September 2025, Vivesto AB highlighted significant progress in its strategic focus on high-potential areas like its veterinary oncology program Paccal Vet and the Cantrixil program for hematological cancers. The company reported no net sales for the period, but showed a reduced operating loss compared to the previous year, reflecting cost efficiencies and strategic resource allocation. Key developments included positive interim results from clinical studies of Paccal Vet in dogs and cats, as well as promising preclinical results for Cantrixil in acute myeloid leukemia. Vivesto is actively seeking strategic partnerships to further clinical development and commercialization efforts. Looking ahead, Vivesto’s management remains optimistic about the company’s potential to achieve significant milestones in the coming year, supported by its strategic focus and financial backing from its main shareholder.